Résonance magnétique cardiaque (RMC) c’est une technique sans rayonnement, qui est considérée comme l’étalon-or pour l’évaluation de l’anatomie cardiaque, de la fonction et même de la composition des tissus. L’essai RESILIENCE utilisera la RMC comme principale méthodologie de mesure des résultats, et les patients inscrits à l’essai subiront 3 examens pendant toute la durée de l’étude.
Essai clinique multinational, prospectif, de preuve de concept de phase II, à double insu, contrôlé par simulation, randomisé (ECR) pour évaluer l’efficacité et l’innocuité du préconditionnement ischémique distal (RIC) chez les patients atteints de Lymphome recevant des anthracyclines. Les patients devant subir ≥5 cycles de chimiothérapie seront éligibles.
On Thursday, November 16th at 19:00 hours we will organize the “RESILIENCE Workshop and laboratory visit. Surviving cancer with a strong heart” within the activities held in Madrid on the occasion of the Science and Innovation Week. The “RESILIENCE Workshop and laboratory visit. Surviving cancer with a strong heart” will consist of a free activity, for
During the Global Cardio Oncology Summit 2023, that took place in Madrid last September 27th, we had the opportunity of listening Dr. Borja Ibáñez, coordinator of RESILIENCE project and Scientific Director of CNIC, discussing with Dr. Bonnie Ky, Director of the Penn Center for Quantitative Echocardiography and Thalheimer Center for
The European Society of Cardiology (ESC) through the ESC Council of Cardio-Oncology will host on October 19th the first multi-stakeholder meeting in the context the RESILIENCE project, funded by the European Commission, to share the latest results with different stakeholders and patients. The event will focus on emerging therapies for
RESILIENCE Project will participate on Friday, September 29th in the XIV European Researchers Night in Madrid with an activity in which the public of all ages can attend, free of charge, with prior registration. The “RESILIENCE Workshop and laboratory visit. Surviving cancer with a strong heart” where we will have
The RESILIENCE trial has expanded its inclusion criteria to allow more types of lymphoma to be included in the trial. These changes are proposed after having agreed with the recruiting hospitals. To date, only patients with a specific type of lymphoma (non-Hodgkin) were included, but after a careful study by
On Friday June 16th we made the initial visit at the San Carlos Clinical Hospital in Madrid and it is with great pleasure that we welcome this Hospital to our RESILIENCE project, in which we work hard every day to help people survive cancer with a strong heart. During the
